Basic Info
  • Grade: pharmaceutical grade

    Factory Location: Shanghai

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Enritinib is an oral bioavailable inhibitor of tyrosine kinase tropomyosin receptor kinases (Trk) A, B, and C, C-ros oncogene 1 (ROS1), and anaplastic lymphoma kinase (ALK), with potential anti-tumor activity. After administration, enrotinib binds and inhibits TrkA, TrkB, TrkC, ROS1, and ALK. Inhibiting these kinases may lead to interruption of signal transduction mediated by TrkA -, TrkB -, TrkC -, ROS1-, and ALK. This leads to induction of apoptosis and inhibition of tumor cell proliferation in tumor cells expressing these kinases. TrkA, TrkB, TrkC, ROS1, and ALK are overexpressed in various types of cancer cells.
Send your message to this supplier
  • From:
  • To:
    Shanghai Hope-chem Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service